← Investor PortalInterested in the Company? Request more Information

BT759112

This biotech company is pioneering the future of age-related disease treatment with cutting-edge gene therapies designed to restore youthful cellular function. By leveraging partial cellular reprogramming, it is developing tissue-specific gene therapies targeting neurodegenerative diseases, starting with Alzheimer’s. Unlike conventional treatments that only manage symptoms, this approach aims to reverse the aging process at the cellular level, addressing the root cause of disease.
‍
With a clear roadmap toward clinical trials, strong partnerships with top-tier researchers, and a rapidly expanding market, this company is positioned to become a dominant player in the next generation of biotech innovation.

Overview

  • Industry: Biotech & Gene Therapy
  • Founded: 2021
  • Location: U.S.-based, operating in a leading biotech hub
  • Core Focus: Developing tissue-specific gene therapies to reverse aging at the cellular level, starting with Alzheimer’s
  • Technology: Partial cellular reprogramming to restore youthful gene expression in targeted tissues
  • Development Stage: Preclinical; IND-enabling studies in progress
  • Intellectual Property: PCT patent filed
  • Funding Required: $10M for clinical advancement and manufacturing setup

Problem & Solution

  • The Problem

    → Alzheimer’s affects 55M people globally, with costs exceeding $1T annually.
    → No current cure—existing treatments only manage symptoms rather than addressing the root cause.
    → Aging population is driving demand, with Alzheimer’s cases expected to triple by 2050.
  • The Solution

    → Tissue-specific gene therapies reset cellular gene expression to a youthful state, directly reversing neurodegeneration at its source.
    → Unlike conventional treatments, this approach aims for disease modification rather than temporary relief.
    → This technology positions the company at the forefront of next-generation biotech innovation.

Market Potential

  • Target Market: Alzheimer’s patients (55M worldwide, 22M in the US & EU).
  • Market Size:

    → TAM: $550B annually
    → SAM: $220B annually
    → SOM: $11B–$22B (5-10% penetration)
  • Growth Rate: Alzheimer’s treatment market growing at 6-7% annually.
  • Key Trends: Aging population, rising healthcare costs, and growing demand for disease-modifying treatments.

Product & Technology

  • Lead product: Gene therapy targeting Alzheimer’s, utilizing partial cellular reprogramming to rejuvenate brain cells.
  • Pipeline: Expanding into Parkinson’s, stroke recovery, and other age-related conditions.
  • Current Stage: Preclinical; IND-enabling studies in progress.
  • Scientific Validation:

    → Breakthrough results in animal studies, showing reversal of cognitive decline.
    → Collaboration with top-tier research labs, including leading pioneers in cellular reprogramming.

Business Model

  • Primary Revenue Model: Licensing and partnerships with large pharmaceutical companies post-clinical validation.
  • Revenue Streams:

    → Upfront licensing fees
    → Development and regulatory milestone payments
    → Royalties on future sales
  • Go-to-Market Strategy: Partner with biotech and pharma leaders to accelerate commercialization and distribution.

Financials

  • Current Burn Rate: $20K/month
  • Runway: 6 months (pre-funding)
  • Total Funding to Date: $1.1M
  • Projected Runway: 3 years with new funding.

Team

  • Led by a team of experienced entrepreneurs, scientists, and industry experts with deep expertise in gene therapy, biotechnology, and business strategy.
  • Chief Executive Officer – A biotech entrepreneur with over a decade of experience translating scientific breakthroughs into therapies. Strong expertise in drug discovery and neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and stroke.
  • Chief Scientific Officer – A world-renowned expert in aging research and molecular biogerontology with over 100 publications. Has held senior academic positions and led groundbreaking studies in cellular rejuvenation.
  • Chief Financial Officer – A finance specialist with 20+ years of experience in biotech investment banking and private equity. Previously managed financial strategies for high-growth biotech startups.
  • Chief Medical Officer (Planned Hire) – Will bring expertise in GMP manufacturing and clinical development, guiding the company through regulatory approvals and clinical trials.
  • Scientific Advisors & Collaborators – Includes leading experts in partial cellular reprogramming, gene therapy, and neurodegeneration, including pioneers in the field of age-related disease treatment.

Competitive Edge

  • Focused on CNS-specific therapies, unlike competitors with broad aging approaches.
  • Exclusive partnerships with top researchers in gene reprogramming.
  • Proven animal model success, demonstrating cognitive restoration in aged mice.
  • Tissue-specific approach, avoiding risks of dedifferentiation seen in other longevity therapies.
  • Large pharmaceutical exit potential, targeting an unmet need in a trillion-dollar market.

Traction & Milestones

  • Four successful animal studies, showing significant cognitive restoration.
  • Scientific breakthrough in Alzheimer’s reversal, validated in preclinical models.
  • Strategic research partnerships with leading gene therapy labs.
  • PCT patent filed, protecting novel reprogramming factors and gene delivery platform.
  • Upcoming FDA INTERACT meeting to align on clinical development plans.

Risks & Mitigation

  • Market Competition: Differentiated CNS-specific approach with proven results.
  • Operational Complexity: Partnering with CDMOs for GMP manufacturing.
  • Financial Constraints: Milestone-based fundraising and potential non-dilutive grants.
  • Regulatory Hurdles: Engaging FDA early to streamline approvals.

Funding Requirements

  • Funding Required: $10M
    ‍    → $6M: Product development (FDA prep, IND-enabling studies, regulatory submission)
    → $2.5M: GMP manufacturing setup for clinical trials
    → $1M: Key hires, including a Chief Medical Officer
    → $0.5M: Advanced R&D for second-generation therapies

Exit Strategy

  • Acquisition: Large pharmaceutical companies (e.g., Biogen, Novartis, Roche) looking for breakthrough Alzheimer’s treatments.
  • IPO: Going public to scale pipeline expansion and fund late-stage clinical trials.
  • Strategic Partnerships: Licensing agreements with biotech giants for commercialization.
  • Projected Exit Timeline: 4-5 years.

Why Invest?

  • Massive Market Potential: $550B+ Alzheimer’s treatment market.
  • Disruptive Technology: First-of-its-kind gene therapy targeting aging at its root cause.
  • Strong Scientific Backing: Exclusive research collaborations with leading labs.
  • Validated Preclinical Results: Proven memory restoration in aged mice.
  • High Exit Potential: Acquisition or IPO within 4-5 years.

Pitch Deck

View the deck through the link below—while some unique identifiers have been removed, it still offers a great overview. For access to detailed investor materials, please reach out to us, as full decks are only shared upon request to maintain confidentiality and exclusivity.

View Pitch Deck

Interested in the startup?

Let us know, if you'd like to request more information about the company, or if you'd like to hear a great pitch first.

Investor Interest Form